Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

Autor: Thomas Monfeuga, Jenny Norlin, Anne Bugge, Elisabeth D. Gaalsgaard, Cesar A. Prada-Medina, Markus Latta, Sanne S. Veidal, Pia S. Petersen, Michael Feigh, Dorte Holst

Publikováno v: Molecular Metabolism, Vol 79, Iss , Pp 101850- (2024)

Objective: The metabolic benefits of GLP-1 receptor (GLP-1R) agonists on glycemic and weight control are well established as therapy for type 2 diabetes and obesity. Glucagon's ability to increase energy expenditure is well described, and the combina

Externí odkaz: https://doaj.org/article/b046605cf4e74e3997c9fe7753652fe9

A lipopolysaccharide mouse model mirrors neuroinflammatory transcriptional signatures of human Alzheimer’s disease, and the Glucagon‐Like Peptide‐1 receptor agonist semaglutide attenuates neuroinflammation in this model

Autor: Mette Q Ludwig, Dylan M Belmont‐Rausch, Marie Aare Bentsen, Anna Secher, Stine A Normann Hansen, Kristoffer L Egerod, Charlotte Thim Hansen, Kevin D Dalgaard, Myrte Merkestein, Dorte Holst, Charles Pyke, Franziska Wichern, Joseph Polex‐Wolf, Tune H Pers, Lotte Bjerre Knudsen

Publikováno v: Alzheimer's & Dementia. 18

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0aa4a8f8326c5665e85e9928b51f0348
https://doi.org/10.1002/alz.063862

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease

Autor: Adrian McCann, Anne Bugge, Mikkel Werge, Nicolai J. Wewer Albrechtsen, Dorte Holst, Lise Lotte Gluud, Elisabeth D. Galsgaard

Publikováno v: Journal of Clinical Medicine, Vol 10, Iss 1081, p 1081 (2021)
Werge, M P, McCann, A, Galsgaard, E D, Holst, D, Bugge, A, Albrechtsen, N J W & Gluud, L L 2021, ' The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease ', Journal of Clinical Medicine, vol. 10, no. 5, 1081 . https://doi.org/10.3390/jcm10051081
Journal of Clinical Medicine

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing and approximately 25% of the global population may have NAFLD. NAFLD is associated with obesity and metabolic syndrome, but its pathophysiology is complex and only partly under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae2f973fd4364f2fcc62945d52c9cea1
https://www.mdpi.com/2077-0383/10/5/1081

FRI-305-Long acting GLP-1/Glucagon co-agonist ameliorates steatosis, inflammation and fibrogenesis in a rodent model of NASH

Autor: Kirsten Raun, Jenny Norlin, Anne Bugge, Elisabeth D. Galsgaard, Thomas Kruse Hansen, Markus Latta, Jesper Lau, Dorte Holst

Publikováno v: Journal of Hepatology. 70:e529-e530

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3aa88f2511b9d137441bc990af905482
https://doi.org/10.1016/s0618-8278(19)31048-5

An Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor Possessing Cognition-Enhancing Properties in Vivo

Autor: Daniel B, Timmermann, Jens Halvard, Grønlien, Kathy L, Kohlhaas, Elsebet Ø, Nielsen, Eva, Dam, Tino D, Jørgensen, Philip K, Ahring, Dan, Peters, Dorte, Holst, Jeppe K, Christensen, Jeppe K, Chrsitensen, John, Malysz, Clark A, Briggs, Murali, Gopalakrishnan, Gunnar M, Olsen

Publikováno v: Journal of Pharmacology and Experimental Therapeutics. 323:294-307

Augmentation of nicotinic alpha7 receptor function is considered to be a potential therapeutic strategy aimed at ameliorating cognitive and mnemonic dysfunction in relation to debilitating pathological conditions, such as Alzheimer's disease and schi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec2e19ee44a779ae070e47722f0a55be
https://doi.org/10.1124/jpet.107.120436